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ACVR2B/Fc counteracts 
chemotherapy-induced loss of 
muscle and bone mass
Rafael Barreto1, Yukiko Kitase2,3, Tsutomu Matsumoto2,3, Fabrizio Pin2,3, Kyra C. 
Colston4, Katherine E. Couch4, Thomas M. O’Connell3,5,6,7, Marion E. Couch3,5,6,7, Lynda F. 
Bonewald2,3,6,7 & Andrea Bonetto1,2,3,5,6,7
Chemotherapy promotes the development of cachexia, a debilitating condition characterized by muscle 
and fat loss. ACVR2B/Fc, an inhibitor of the Activin Receptor 2B signaling, has been shown to preserve 
muscle mass and prolong survival in tumor hosts, and to increase bone mass in models of osteogenesis 
imperfecta and muscular dystrophy. We compared the effects of ACVR2B/Fc on muscle and bone mass 
in mice exposed to Folfiri. In addition to impairing muscle mass and function, Folfiri had severe negative 
effects on bone, as shown by reduced trabecular bone volume fraction (BV/TV), thickness (Tb.Th), 
number (Tb.N), connectivity density (Conn.Dn), and by increased separation (Tb.Sp) in trabecular bone 
of the femur and vertebra. ACVR2B/Fc prevented the loss of muscle mass and strength, and the loss of 
trabecular bone in femurs and vertebrae following Folfiri administration. Neither Folfiri nor ACVR2B/Fc 
had effects on femoral cortical bone, as shown by unchanged cortical bone volume fraction (Ct.BV/TV), 
thickness (Ct.Th) and porosity. Our results suggest that Folfiri is responsible for concomitant muscle and 
bone degeneration, and that ACVR2B/Fc prevents these derangements. Future studies are required to 
determine if the same protective effects are observed in combination with other anticancer regimens or 
in the presence of cancer.
It is estimated that 1.7 million new cases of cancer will be diagnosed in the United States this year, and up to 
600,000 people will die from the disease1. Up to 80% of all advanced cancer patients will present with signs 
of cachexia. This condition is characterized by depletion of skeletal muscle mass and adipose tissue, persistent 
muscle fatigue, anorexia, increased inflammatory state, worsened quality of life and overall shorter survival2–6. 
Experimental evidence suggests that bone loss, a disorder that primarily occurs concurrent to the formation of 
distal metastases in lung carcinomas, prostate and breast cancer7,8, is also a primary feature accompanying the 
development of a severe cachectic phenotype. This phenotype has been described in myeloma, colorectal and 
pancreatic cancers and burn-induced cachexia9–13.
Notably, musculoskeletal degenerations, often culminating with extensive muscle and bone loss, are the most 
common and most distressing symptoms associated with the development of cancer, as well as with its manage-
ment and treatment7,14–16. We recently showed that anti-cancer regimens routinely used for the therapy of solid 
tumors, such as Folfiri (a combination of 5-fluorouracil, leucovorin and irinotecan), contribute to the develop-
ment of cachexia and promote the loss of muscle tissue and muscle strength17. Similarly, chemo- and radiotherapy 
have been reported to play a role in bone loss by directly targeting bone mass18,19, promoting indirect systemic 
effects20,21, affecting bone remodeling22,23 or causing myelosuppression24,25.
The identification of muscle- and bone-derived factors for the generation of new treatment strategies is far 
from being accomplished. No effective therapy is currently approved for the concurrent treatment of muscle 
wasting and osteoporosis associated with cancer growth or anti-cancer therapies. It is estimated that cachexia 
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ultimately accounts for 25–30% of all cancer-related deaths each year, thereby representing an important clinical 
problem4,26. While no therapies are available for the treatment of cancer-associated muscle wasting, only a few 
compounds, e.g. bisphosphonates and denosumab, are approved for the prevention of bone loss in combination 
with cancer or chemotherapy, although issues related to limited efficacy and long-term side effects have been 
reported in some cases27. Similarly, other compounds, such as the parathyroid hormone (PTH) and PTH-related 
protein (PTHrP) peptides, are currently being tested, while their limited applicability in association with cancer 
still needs to be clarified28–30.
In an attempt to isolate novel compounds endowed with muscle- and bone-protective properties, inhibition 
of the activin receptor 2B (ACVR2B) signaling was shown to enhance muscle mass, increase overall survival in 
experimental cancer cachexia31,32, and to ameliorate the dystrophic phenotype in mdx mice33. We and others 
showed that ACVR2B/Fc, a soluble ACVR2B fusion protein and inhibitor of receptor downstream signaling34, 
potently counteracts the Folfiri-associated myofiber atrophy in C2C12 cultures17 and prevents muscle wasting in 
combination with doxorubicin35 or cisplatin36. Administration of ACVR2B/Fc was also shown to concurrently 
prevent bone loss in a mouse model of osteogenesis imperfecta37 and in dystrophic mice38.
We hypothesized that inhibition of the activin signaling by means of ACVR2B/Fc could represent a novel 
strategy to treat musculoskeletal conditions associated with chemotherapy treatments, thereby improving both 
muscle and bone properties. To test our hypothesis, we treated CD2F1 mice with Folfiri, ACVR2B/Fc, or a combi-
nation of both for up to five weeks, and the effects on muscle size and strength were evaluated. In addition to mus-
cle mass and function, we assessed the effects on bone mass, specifically trabecular bone volume fraction (BV/
TV), thickness (Tb.Th), number (Tb.N), connectivity density (Conn.Dn), and trabecular separation (Tb.Sp) in 
trabecular bone of the femur and vertebra. In order to better understand the consequence of ACVR2B/Fc admin-
istration to healthy animals and mice treated with Folfiri, we also assessed the circulating levels of IL-6 and activin 
A, previously reported to play a major role in promoting cachexia and in the regulation of muscle and bone mass.
Results
ACVR2B/Fc preserves body weight in animals exposed to Folfiri. In order to test the use of 
ACVR2B/Fc for the prevention of chemotherapy-derived loss of muscle mass and muscle strength, we took 
advantage of a previously characterized experimental model17. CD2F1 male mice (8 week-old) received Folfiri 
(twice/weekly, i.p.), with or without ACVR2B/Fc (once/weekly, i.p.), for up to 5 weeks (Fig. 1). Consistent with 
our previous data17,39, after an initial lag phase, the animals that were treated with Folfiri lost about 20% of their 
body weight (−5.21 ± 0.32 g; p < 0.001 vs. Vehicle). The animals receiving the combination of Folfiri + ACVR2B/
Fc displayed a substantial preservation of body mass (2.36 ± 1.14 g; p < 0.001 vs. Folfiri) when compared to the 
Vehicle-treated animals (2.13 ± 0.71 g) (Fig. 2A,B). The animals administered the ACVR2B/Fc alone showed 
a marked increase in body weight (5.73 ± 0.32 g; p < 0.001 vs. Vehicle), in line with previous findings31,34 
(Fig. 2A,B). The assessment of the body composition performed by means of EchoMRI showed a precocious loss 
of fat tissue in the animals receiving Folfiri that ultimately was only partially preserved by ACVR2B/Fc treatment 
(Fig. 3). In line with the body weight data shown in Fig. 2, the administration of ACVR2B/Fc promoted general 
muscle hypertrophy and completely counteracted the loss of lean tissue as mediated by Folfiri treatment (Fig. 3).
Administration of ACVR2B/Fc protects muscle mass in Folfiri-treated mice. In line with our pre-
vious studies17,39, chronic administration of Folfiri to male CD2F1 mice led to marked loss of muscle tissue com-
pared to the Vehicle-treated animals. Specifically, the chemotherapy-induced muscle wasting was consistent with 
markedly reduced size of tibialis anterior (−22%; p < 0.001), gastrocnemius (−22%; p < 0.001), quadriceps (−26%; 
p < 0.001) and heart (−13%; p < 0.001) (Fig. 4). To better understand whether gender-specific effects could affect 
the chemotherapy-associated muscle toxicity, we tested Folfiri also in female CD2F1 mice. Interestingly, the admin-
istration of the same chemotherapy regimen to female mice was promoting the occurrence of significant depletion 
of muscle mass (e.g. gastrocnemius: −13% vs. Vehicle; p < 0.05) and reduced muscle strength (−7% vs. Vehicle; 
p < 0.05) (Supplementary Figure S1). However, the chemotherapy-associated effects seemed to be less pronounced 
in the females, showing moderate loss of muscle mass and muscle weakness with respect to the males. Hence, 
we investigated the muscle-protective properties of ACVR2B/Fc in the male mice only, due to their apparently 
enhanced susceptibility to the effects of anti-cancer agents. ACVR2B/Fc was able to promote muscle hypertrophy, 
as shown by increased quadriceps size (+36% vs. Vehicle; p < 0.001), and to completely reverse the Folfiri-induced 
muscle atrophy (+13% vs. Folfiri; p < 0.001) (Fig. 4). ACVR2B/Fc treatment also caused moderate hepatomegaly 
Figure 1. Experimental plan. Schematic representation of the experimental model and dosing schedules. The 
black ticks indicate the days, the blue arrows the day of ACVR2B/Fc treatment and the red arrows the day of 
Folfiri treatment. Wk. = week.
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(+15% vs. Vehicle; p < 0.01) and only partially restored the fat tissue in the Folfiri-treated mice (+53% vs. Folfiri; 
p < 0.05). No change in spleen size was recorded in any of the experimental groups (Fig. 5).
ACVR2B/Fc preserves muscle size and muscle strength in animals receiving Folfiri. Similar 
to Fig. 4, fiber hypertrophy was displayed in the tibialis anterior muscle following treatment with ACVR2B/Fc 
(+48%; p < 0.001 vs. Vehicle), while its administration in combination with chemotherapy presented a complete 
preservation of fiber size vs. the Folfiri-treated animals (+82%; p < 0.001) (Fig. 6A). Weekly ACVR2B/Fc treat-
ment, combined with chemotherapy, not only was able to fully counteract the muscle weakness associated with 
Folfiri (+38%; p < 0.001), but also induced a significant increase in muscle strength respect to the Vehicle-treated 
animals (+11%; p < 0.001) (Fig. 6B).
ACVR2B/Fc prevents Folfiri-induced loss of trabecular bone mass. In order to verify whether 
the Folfiri-associated effects on skeletal muscle mass were reflected in a similar manner in bone, sections from 
femurs and vertebrae extracted from animals exposed to Folfiri and ACVR2B/Fc were analyzed by microcom-
puted tomography. The animals exposed to Folfiri treatment exhibited a severe loss of trabecular bone but not 
cortical bone in the femur (Fig. 7). This was evidenced by markedly reduced trabecular bone volume fraction 
(BV/TV; +79%; p < 0.001), thickness (Tb.Th; −26%; p < 0.001), number (Tb.N; −72%; p < 0.001) and connec-
tivity density (Conn.Dn; −39%; p < 0.01), as well as increased trabecular separation (Tb.Sp; +91%; p < 0.001) vs. 
Vehicle (Fig. 7A,B). The administration of ACVR2B/Fc alone not only enhanced the trabecular BV/TV (+73%; 
p < 0.001), Tb.Th (+21%; p < 0.01) and Tb.N (+44%; p < 0.001) vs. the Vehicle-treated mice, but also signif-
icantly protected the trabecular bone when combined with Folfiri, as shown by ameliorated BV/TV (+247%; 
p < 0.001), Tb.Th (+42%; p < 0.001), Tb.Sp (−36%; p < 0.001), Tb.N (+147%; p < 0.001) (Fig. 7A,B). Unlike 
the trabecular bone, the femural cortical bone was not affected by any of the treatments, as shown by unchanged 
cortical bone volume fraction (Ct.BV/TV), thickness (Ct.Th) and Porosity (Fig. 7C,D). The vertebral trabecular 
bone was also affected by Folfiri, as shown by reduced BV/TV (−51%; p < 0.001) and Tb.N (−49%; p < 0.001), 
Figure 2. ACVR2B/Fc prevents chemotherapy-induced body weight loss. Body weight curves (A) and body 
weight change (i.e. body weight at time of sacrifice vs. initial body weight) (B) in mice exposed to Folfiri 
and ACVR2B/Fc for up to 5 weeks (n = 6–7). Data expressed as means ± SD. Significance of the differences: 
***p < 0.001 vs. Vehicle; §§§p < 0.001 vs. Folfiri.
Figure 3. ACVR2B/Fc administration abolishes muscle depletion and partially protects against fat loss in mice 
treated with Folfiri. Body composition assessment in animals exposed to Folfiri and ACVR2B/Fc (n = 6–7) was 
performed by means of EchoMRI. Data (grams of fat or lean tissue) are expressed as fold change variation vs. 
baseline (day 0) over 5 weeks. Significance of the differences: *p < 0.05, **p < 0.01, ***p < 0.001 vs. Vehicle; 
§§p < 0.01, §§§p < 0.001 vs. Folfiri.
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and by increased Tb.Sp (+44%; p < 0.001) with respect to the Vehicle-treated mice (Fig. 8A,B). The ACVR2B/
Fc administration was able to counteract the Folfiri-associated effects in trabecular bone in both femur and ver-
tebrae, thereby improving BV/TV (+112%; p < 0.001), Tb.Th (+17%; p < 0.05), Tb.Sp (−28%; p < 0.001), Tb.N 
(+82%; p < 0.001) (Fig. 8A,B).
Figure 4. Administration of ACVR2B/Fc prevents muscle atrophy in the Folfiri-treated. Muscle weights in 
mice treated with Folfiri and ACVR2B/Fc for up to 5 weeks (n = 6–7). Weights were normalized to the Initial 
Body Weight (IBW) and expressed as weight/100 mg IBW. Data expressed as means ± SD. GSN: gastrocnemius. 
Significance of the differences: *p < 0.05, ***p < 0.001 vs. Vehicle; §§§p < 0.001 vs. Folfiri.
Figure 5. Folfiri-induced adipose tissue depletion is partially prevented by ACVR2B/Fc treatment. Liver, 
spleen and fat weights in mice treated with Folfiri and ACVR2B/Fc for up to 5 weeks (n = 6–7). Weights 
were normalized to the Initial Body Weight (IBW) and expressed as weight/100 mg IBW. Data expressed as 
means ± SD. Significance of the differences: **p < 0.01, ***p < 0.001 vs. Vehicle; §p < 0.05 vs. Folfiri.
Figure 6. ACVR2B/Fc prevents the Folfiri-associated loss of muscle fiber size and muscle strength. Muscle 
morphology (H&E staining) and quantification of the cross-sectional area (CSA) in the tibialis anterior muscle 
of mice exposed to chemotherapy or ACVR2B/Fc. Scale bar: 100 μm. Magnification: 20X (A). Whole body 
grip strength in animals administered chemotherapy or ACVR2B/Fc for up to 5 weeks, reported as peak force, 
was measured by taking advantage of a grip strength meter and expressed as the average of the three top pulls 
from each animal (n = 6–7) (B). Data expressed as means ± SD. Significance of the differences: **p < 0.01, 
***p < 0.001 vs. Vehicle; §§§p < 0.001 vs. Folfiri.
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ACVR2B/Fc reduces IL-6 and activin A in combination with chemotherapy. In order to better 
understand the effects associated with the administration of ACVR2B/Fc to healthy animals and mice treated 
with Folfiri, we assessed the circulating levels of IL-6 and activin A, previously reported to play a major role in 
promoting cachexia and in the regulation of muscle and bone mass17,39. In our animal model, the administration 
of Folfiri for up to 5 weeks resulted into markedly elevated IL-6 (∼36-fold increase vs. Vehicle; p < 0.001), which 
was completely prevented in combination with ACVR2B/Fc (p < 0.001 vs. Folfiri) (Fig. 9). On the other hand, 
despite being more elevated (+93%) following Folfiri treatment, activin A was not statistically different compared 
to the vehicle-treated animals. Interestingly, the combined administration of ACVR2B/Fc resulted into reduced 
activin A with respect to the animals receiving Folfiri (−63%; p < 0.05) or the vehicle (−30%; p < 0.05) (Fig. 9).
Discussion
Cancer development often contributes to the loss of muscle mass and muscle strength, compromising the over-
all quality of life by decreasing both productivity and physical functioning40–44. Similarly, despite the recent 
development of novel and more effective treatment strategies capable of significantly improving life expectancy, 
Figure 7. Folfiri severely affects the trabecular bone mass, but not the cortical bone, in the mouse femurs, 
and ACVR2B/Fc completely abolishes its effects. Quantification of bone volume fraction (BV/TV), trabecular 
thickness (Tb.Th), trabecular separation (Tb.Sp), trabecular number (Tb.N) and trabecular connectivity 
density (Conn.Dn) in the femur of mice treated with Folfiri and ACVR2B/Fc (n = 6–7) (A). Representative 
3D rendering of μCT scan images of femur sections (B). Quantification of cortical bone volume fraction (Ct.
BV/TV), cortical thickness (Ct.Th) and overall porosity in the femur of mice exposed to Folfiri and ACVR2B/
Fc (n = 6–7) (C). 3D rendering of μCT scan images of cortical femur sections (D). Data are expressed as 
means ± SD. Significance of the differences: *p < 0.05, **p < 0.01, ***p < 0.001 vs. Vehicle; §§§p < 0.001 vs. 
Folfiri.
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the administration of anti-cancer therapies is known to adversely affect patients’ quality of life by producing 
mild-to-severe side effects. Nausea, diarrhea, anorexia and increased fatigue are the most relevant45–47.
We and others have reported that anti-cancer therapies cause a decline of muscle size and function (i.e. 
cachexia) in both animal models and cancer patients17,47–50. Notably, the chemotherapy-associated muscle 
functional deficits have been shown to positively correlate with both enhanced mortality2,51 and aggressive-
ness of chemotherapy52,53. Further, these complications have been reported to cause difficulty for patients to 
adhere to or complete treatment regimens, for delays in treatment, to cause dose limitation, and for discon-
tinuation of therapy in cancer patients54,55. No remedies have been identified to relieve such conditions thus 
far, and the chemotherapy-associated muscle defects have been shown to persist for months to years following 
remission17,56–62.
Figure 8. ACVR2B/Fc prevents the Folfiri-mediated effects on vertebral bone tissue. Quantification of bone 
volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), trabecular number 
(Tb.N) and trabecular connectivity density (Conn.Dn) in the vertebrae of mice treated with Folfiri and 
ACVR2B/Fc (n = 6–7) (A). Representative 3D rendering of μCT scan images of vertebral sections (B). Data are 
expressed as means ± SD. Significance of the differences: *p < 0.05, ***p < 0.001 vs. Vehicle; §§§p < 0.001 vs. 
Folfiri.
Figure 9. ACVR2B/Fc treatment potently reduces IL-6 and Activin A circulating levels in combination with 
Folfiri. Quantification of IL-6 and Activin A levels in the plasma from mice exposed to Folfiri, alone or in 
combination with ACVR2B/Fc (n = 6–7). Data, expressed as means ± SD, are reported in pg/ml. Significance of 
the differences: ***p < 0.001 vs. Vehicle; §p < 0.05, §§§p < 0.001 vs. Folfiri.
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In a similar manner, significant loss of bone mass was described in patients undergoing adjuvant chemother-
apy for various gynecologic cancers63,64 and radiotherapy for abdominal tumors65. A variety of hormonal and 
non-hormonal compounds, frequently used in patients affected with breast and prostate cancer, was shown to 
promote bone resorption and bone turnover. This contributed to the development of bone loss and to the exacer-
bation of the overall mortality7. Therefore, the occurrence of bone fractures in patients with cancer or undergoing 
chemo-radiotherapy represents a problem of significant concern and deserves major attention.
Over the past 50 years, fluoropyrimidines, such as 5-fluorouracil (5-FU), have remained one of the most 
commonly used antimetabolite drugs. They have been prescribed for the therapy of metastatic colorectal cancers, 
resulting in significant increases in survival rates, particularly in combination with leucovorin66 and irinotecan, a 
topoisomerase I inhibitor67. This treatment regimen, known as Folfiri, is routinely used as a first-line chemother-
apy regimen for the treatment of metastatic colorectal cancer alone, and can also be used in combination with 
other anti-cancer compounds, such as bevacizumab, aflibercept, cetuximab or panitumumab, to improve efficacy 
and response rates68,69.
In the present study we investigated the muscle and bone toxicities associated with the administration of 
Folfiri. This systemic chemotherapy regimen can have a major impact on patients’ quality of life and is often 
responsible for severe side effects, including myelotoxicity, gastrointestinal toxicity, enhanced morbidity and 
occasional mortality70. In line with our previous findings17, we report that prolonged in vivo Folfiri treatment 
accounts for severe effects on skeletal and to a lesser extent, cardiac muscles, in both male and female mice. 
Progressive loss of myofiber size and muscle strength occurs in animals exposed to this treatment for up to 5 
weeks. Folfiri is also associated with a marked loss of adipose tissue, thereby contributing to the establishment of 
a general cachectic phenotype17,39. Interestingly, the effects described in the females were less pronounced, sug-
gesting that gender-specific effects may play a role in determining drug toxicity. This is also in line with previous 
reports showing that females are likely more resistant to high-dose chemotherapy and have increased likelihood 
of receiving second-line anti-cancer therapies for the treatment of lung cancer71–73.
We also showed for the first time that chronic administration of Folfiri also associates with unexpected and 
severe trabecular bone loss in normal animals. Ours is not the first report to show that anti-cancer drugs may 
affect bone strength and quality. Indeed, Fonseca et al. previously reported that anti-cancer drugs, such as dox-
orubicin, routinely used in pediatric cancer treatment, not only promote muscle wasting35, but also negatively 
affects the overall bone morphology, as well as the femur mechanical properties in rats74. This is of particular 
importance, especially considering that patients affected with metastatic colorectal cancer usually undergo mul-
tiple rounds of chemotherapy treatment, thereby having far more chances to develop such toxicity. In addition 
we found that the cortical bone, however, did not seem to be significantly affected, at least within this time frame. 
This apparent discrepancy could be interpreted by the fact that the cortical bone, which accounts for 80% of the 
adult human skeleton, is typically less metabolically active than the trabecular bone75, and therefore likely less 
susceptible of the anti-proliferative and cytotoxic effects associated with the administration of chemotherapy. 
These effects may also be explained by the fact that 5-FU, one of the main components of the Folfiri regimen, 
was shown to cause marked bone loss in rats after only five consecutive days of treatment, possibly by induc-
ing inflammation, suppressing osteoblast activity and enhancing osteoclast recruitment, therefore promoting an 
unbalance in bone remodeling76. Recent findings from Fen et al. showed that six cycles of 5-FU combined with 
cyclophosphamide and epirubicin, one of the preferred chemotherapy regimens for the treatment of breast can-
cer, were able to promote severe loss of trabecular bone, reduction of bone marrow cells and marrow adiposity in 
experimental animals77.
The investigation of muscle/bone crosstalk has failed to identify new targets for the treatment of 
chemotherapy-associated muscle wasting and osteoporosis. Unfortunately, only a few therapies, characterized 
by high cost and occasional long-term toxicities, are available to date. They include anti-resorptive drugs, such 
as the bisphosphonates, which are routinely used for the treatment and prevention of osteoporosis and bone 
fractures in cancer patients78,79. Despite this, several side effects, such as acute-phase reactions, nephrotoxicity, 
hypocalcemia and osteonecrosis of the jaw, have been reported27. On the other hand, the PTH peptides represent 
the only approved anabolic therapy currently in use to promote bone formation relative to bone resorption80, a 
process that primarily affects the trabecular bone tissue, whereas the effects on the cortical bone are somewhat 
modest and may depend on the degree of mechanical loading81. Safety and tolerability of these compounds, 
especially after prolonged administration, are still under debate, and their use in cancer patients is being evalu-
ated. Indeed, the 2-year chronic administration of teriparatide, or rhPTH(1–34), a synthetic agonist of human 
PTH currently under investigation for the treatment of postmenopausal osteoporosis, was shown to potentially 
impact carcinogenicity by causing the formation of osteosarcomas in F344 rats, although the same finding has 
not been reported in the clinical setting thus far82,83. Moreover, despite their beneficial effects on bone mass, PTH 
and PTH-related protein (PTHrP) have been described to affect muscle size through the common PTH receptor 
(PTHR)28–30, therefore raising concerns that the administration of PTH peptide in patients with cancer or treated 
with chemotherapy, that are already at risk of significant muscle loss, may instead exacerbate their cachectic con-
dition. Overall, it is known that muscle targeted pro-anabolic strategies can improve survival and quality of life 
in cancer31,32, as well as reduce the toxicity of anticancer drugs17,36. Conversely, it is not completely clear whether 
drugs aimed at primarily preserving bone tissue also play a role in improving the overall outcomes in the presence 
of a tumor. As a matter of fact, no conclusive effects of bisphosphonate administration on delayed cancer recur-
rence and improved survival rates have been reported so far84. Similarly, it is also uncertain if bisphosphonate 
treatment benefits muscle size and function.
In the present study we showed that inhibition of the signaling of the activin type 2B receptor represents a 
potent therapeutic strategy to prevent both muscle and bone loss following chemotherapy treatment. Indeed, 
in our study ACVR2B/Fc, a synthetic fusion peptide inhibitor of the activin receptor type 2B, was able to fully 
restore muscle size and function in cachectic Folfiri-treated mice. This concurs with our previous observations 
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conducted in vitro using a model of chemotherapy-associated myofiber atrophy17. For instance, other reports 
suggest that the blockade of this signaling pathway mitigates the loss of muscle mass and strength in the presence 
of muscle atrophy due to cancer31,32 or its treatments35,36, AIDS85, muscular dystrophy38,86 or disuse78. ACVR2B/
Fc also completely abolished the loss of bone tissue by fully preserving the trabecular bone in the animals exposed 
to Folfiri, as shown by the μCT analysis. Our results are consistent with previous observations reporting beneficial 
effects of ACVR2B/Fc treatment in mice affected with type III osteogenesis imperfecta37 or muscular dystrophy38, 
further showing substantial preservation of bone mass and mechanical properties. Similar to the previously pub-
lished findings79, ACVR2B/Fc displayed bone anabolic properties, as suggested by increased trabecular bone vol-
ume fraction, thickness and number in the femurs of normal mice. Conversely, we did not observe any increase in 
vertebral bone parameters, with the exception of Conn.Dn, in disagreement with Bialek et al.79 Of note, no effect 
of ACVR2B/Fc treatment was observed in cortical bone in our model, in line with prior evidence79.
Overall, the abnormal activation of the signaling pathway downstream of the activin receptors is known to 
play a role in the regulation of both muscle and bone crosstalk, although whether the activin signaling plays a 
more relevant role in promoting bone abnormalities by specifically affecting either the trabecular or the corti-
cal bone remains to be elucidated. Cancer-associated changes in the circulating levels of activin family ligands, 
including activin A, activin B, myostatin and GDF-11, are known to exert effects on muscle and bone homeo-
stasis, thus contributing to the development of overt cachexia87–89. Similarly, Waning et al. suggested that the 
release of TGFβ due to the presence of breast cancer-associated metastatic bone lesions is responsible for muscle 
depletion and weakness90. Further, activin A, also known as a negative regulator of muscle mass and an inde-
pendent prognosis factor of survival in cancer patients88,91,92, was described elevated in the bone matrix and was 
reported to play a role in the regulation of osteoclast induction and bone remodeling93–96. Conversely, its inhibi-
tion by means of a ligand trap soluble receptor was shown to induce bone formation and bone strength in normal 
and diabetic mice, as well as in ovariectomized mice affected with bone loss97,98. Additionally, pro-inflammatory 
cytokines, such as IL-1, IL-6 and TNF, known for their pro-catabolic and anti-anabolic effects in muscle tissue 
and for their relevant role in the pathogenesis of cachexia99–102, have also been shown to interact with activin A by 
exacerbating its detrimental effects in skeletal muscle103,104. In the present study we showed that IL-6 was elevated 
following chemotherapy treatment, and that such effect was potently counteracted by ACVR2B/Fc administra-
tion. This is in contrast with the data reported by Zhou et al., showing no effect of ACVR2B/Fc treatment on 
IL-6 levels in the presence of the C26 tumor32. On the other hand, circulating activin A levels did not seem to 
be affected by the Folfiri treatment, despite a trend towards higher concentrations that was not statistically sig-
nificant, also in line with our initial observations reported in muscle tissue17. However, we should mention that 
in our work activin A was only assessed at time of sacrifice (i.e. three days after the last Folfiri injection; Fig. 1), 
therefore we cannot exclude that higher levels of the same factor may be detected at earlier time points or shortly 
after chemotherapy treatment.
Collectively, the present study shows that depletion of bone tissue occurs concurrently with severe loss 
of muscle mass and function in normal animals exposed to Folfiri. It also validates the blockade of the 
ACVR2B-dependent pathway as a potential new strategy aimed at benefitting cachectic cancer patients under-
going chemotherapy. Based on our and other’s previous observations17,35,77,105, the animal model used in this 
study represents an effective tool to study the musculoskeletal effects of anti-cancer drugs in vivo, a condition 
that must be fulfilled in order to generate meaningful animal results for human translation. Regardless, we are 
aware that this may also represent a limitation of our study, due to the fact that in the clinical setting only subjects 
affected with cancer are normally treated with chemotherapy, therefore possibly preventing us from identifying 
those interactions between tumor- and chemotherapy-driven mediators that may be ultimately responsible for 
the muscle and bone phenotypic alterations.
Furthermore, our data further support the concept that significant communication occurs in normal phys-
iology between two closely related organs, such as muscle and bone106. Indeed, muscle tissue generally behaves 
as an endocrine organ for ‘myokines’ (e.g., IL-6, myostatin, IGF-1) playing a role in bone metabolism and func-
tion106–109. Conversely, bone acts as a storehouse of ‘osteokines’ (e.g., activin A, TGFβ, osteocalcin) released in 
physiologic and pathologic conditions, affecting the functionality of several organs, including skeletal mus-
cle90,110–116. Despite all this, it is not yet known which tissue primarily influences the metabolism and function of 
the other, and whether the bone derangements precede the muscle effects, or vice versa. Additional efforts will 
be required to establish new strategies aimed at detecting early cancer-associated musculoskeletal deficits and at 
counteracting the simultaneous loss of muscle and bone mass following cancer treatments, especially taking into 
consideration that interventions primarily designed to promote muscle growth may also exert beneficial effects 
on bone mass, as well as bone-targeted strategies may additionally benefit skeletal muscle and its function.
Methods
Animals. All animal studies were approved by the Institutional Animal Care and Use Committee at Indiana 
University School of Medicine and were in compliance with the National Institutes of Health Guidelines for Use 
and care of Laboratory Animals and with the 1964 Declaration of Helsinki and its later amendments. For all the 
experiments described, animals were identified with a code and the investigators were blinded during allocation, 
animal handling, and endpoint measurements. Animals (up to 5 per cage) were housed in a pathogen-free facility 
at IU LARC. Male (n = 6–7) and female (n = 5) immunocompetent CD2F1 mice (Envigo, Indianapolis, IN) were 
used. However, after an initial characterization of the muscle-specific effects associated with Folfiri treatment 
alone, only the male mice were examined to investigate the beneficial effects of ACVR2B/Fc administration, in 
continuation with our initial study aimed at determining the effects of commonly-used chemotherapeutics on 
muscle mass and function17. More specifically, the male mice were randomized into four groups, namely Vehicle 
(n = 6), ACVR2B/Fc (n = 6), Folfiri (n = 7) and Folfiri + ACVR2B/Fc (n = 7). The Folfiri-treated animals received 
Folfiri (50 mg/kg 5-Fluorouracil, 90 mg/kg Leucovorin, 24 mg/kg Irinotecan) intraperitoneally (i.p.) twice weekly 
www.nature.com/scientificreports/
9ScIentIfIc RepORts | 7: 14470  | DOI:10.1038/s41598-017-15040-1
for up to 5 consecutive weeks17. The ACVR2B/Fc groups were administered the synthetic peptide once weekly 
(10 mg/kg in sterile PBS; i.p.). The Vehicle-treated animals received equal volumes of solvents only. The animals 
were weighed daily. At sacrifice, several tissues, including skeletal muscles, were collected, weighed, frozen in liq-
uid nitrogen and stored at −80 °C for further studies. The tibialis anterior muscles were rapidly excised, mounted 
in OCT and frozen in N2-cooled isopentane for histology, as previously described117. The mouse carcasses were 
fixed for 2 days in 10% neutral buffered formalin, and then transferred into 70% ethanol for storage of bone and 
other tissues. All chemotherapy drugs were purchased from Sigma Aldrich (St. Louis, MO). ACVR2B/Fc was 
purified from CHO-ACVR2B/Fc conditioned medium118.
Grip strength. The evaluation of the whole body strength in mice was assessed as described in119. Briefly, 
the absolute grip strength (expressed in grams) was recorded by means of grip strength meter (Columbus 
Instruments, Columbus, OH). Overall, 5 measurements were completed and only the top three measurements 
were included in the analysis. In order to avoid habituation, the animals were tested for grip strength no more 
than once weekly.
Body composition assessment. Body composition, e.g. the quantification of lean (muscle) and fat (adi-
pose) mass, was measured once weekly over the entire duration of the experiment in un-anesthetized but physi-
cally restrained mice by means of an Echo Medical systems’ EchoMRI-100 (EchoMRI, Houston, USA), as shown 
in17. This is a moderately stressful analysis, therefore the animals were assessed no more than once weekly. Data 
were expressed as variations over the baseline values.
Measurement of muscle cross-sectional area (CSA). Ten μm-thick cryosections of tibialis anterior 
muscles taken at the mid-belly were processed for Hematoxylin & Eosin staining. All samples were observed 
under an Axio Observer.Z1 motorized microscope (Zeiss, Oberchoken, Germany) and images were recorded for 
morphometric examination. For determination of the cross-sectional area (CSA), muscle fibers (n = 300–500 per 
sample) were measured by tracing the perimeter of each individual fiber using a Cintiq pen tablet input device 
(Wacom, Vancouver, WA, USA) and Image J 1.43 software120.
Micro computed tomography (μCT) analysis of femurs and vertebrae bone morphome-
try. MicroCT (μCT) scanning was performed to measure morphological indices of metaphyseal regions of 
femurs and vertebrae, as described in121. After euthanasia, the mouse carcasses were fixed for 2 days in 10% 
neutral buffered formalin, transferred into 70% ethanol, the right femurs and the fifth lumbar vertebrae dis-
sected, and prepared for μCT scanning on a high-throughput μCT specimen scanner. Bone samples were rotated 
around their long axes and images were acquired using a Bruker Skyscan 1176 (Bruker, Kontich, Belgium) with 
the following parameters: pixel size = 9 μm3; peak tube potential = 50 kV; X-ray intensity = 500 μA; 0.9° rotation 
step. Raw images were reconstructed using SkyScan reconstruction software (NRecon; Bruker, Kontich, Belgium) 
to 3-dimensional cross-sectional image data sets using a 3-dimensional cone beam algorithm. Structural indi-
ces were calculated on reconstructed images using the Skyscan CT Analyzer software (CTAn; Bruker, Kontich, 
Belgium). Cortical and trabecular bone were separated using a custom processing algorithm in CTAn, based 
on the different thicknesses of the structures. Cortical bone was analyzed by threshold 160–255 in the femoral 
mid-shaft. Cortical bone parameters included bone volume fraction (Ct.BV/TV), thickness (Ct.Th), and poros-
ity. Trabecular bone was analyzed between 2.0 mm to 3.0 mm under the femoral distal growth plate and 1 mm 
equally between the distal and proximal growth plates in the fifth lumbar vertebra using a threshold of 80–255. 
Trabecular parameters included bone volume fraction (Tb.BV/TV), number (Tb.N), thickness (Tb.Th), separa-
tion (Tb.Sp), and connectivity (Conn.Dn).
Quantification of circulating IL-6 and activin A. The circulating levels of Activin A (#DAC00B) 
and IL-6 (#M6000B) were measured in mouse poor-platelet plasma by using specific ELISA kits (Bio-Techne 
Corporation, Minneapolis, MN) and following the manufacturer’s protocol.
Statistical analysis. Results are presented as means ± SD. Significance of the differences was determined 
by analysis of variance (ANOVA) followed by Tukey’s post-test. Differences were considered significant when 
p < 0.05.
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